Xeligekimab for moderate to severe palmoplantar pustulosis
Treatments studied
Part of Skin clinical trials.
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have had palmoplantar pustulosis (blisters on palms and soles) for at least 6 months
- Your condition is moderate to severe (based on doctor's assessment)
- You have tried at least one standard treatment (like strong steroids or methotrexate) that didn't work or caused side effects
- You are not using certain other psoriasis treatments (like IL-17, IL-23, or TNF-alpha blockers) within the past 3–4 months
- You do not have other types of psoriasis, active infections, or serious health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tofacitinib and imatinib) for people with moderate-to-severe palmoplantar pustulosis, a painful skin condition affecting the palms and soles. The goal is to see if this combo can reduce pustules and improve symptoms.
This trial tests a new oral medication, ivarmacitinib, for adults with palmoplantar pustulosis (PPP) who haven't gotten better with standard treatments. It aims to see if the drug is safe and effective for reducing the painful pustules on the palms and soles.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This study is testing how well a new medication called Xeligekimab works in real-life settings for people with moderate to severe plaque psoriasis. It may help if you are starting this treatment for the first time and want to contribute to learning more about its effects.
This study tests an experimental drug called HB0034 for people with a sudden, severe flare of generalized pustular psoriasis (GPP). It aims to see if the drug can safely clear the pustules and improve symptoms.
Hear when a new Palmoplantar Pustulosis (PPP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.